Regeneron Pharmaceuticals’ experimental COVID-19 treatment likely provides several months of immunity, Chief Executive Dr. Leonard Schleifer told CBS in an interview that aired Oct. 11.
Schleifer was asked on “Face the Nation” whether the company’s antibody “cocktail,” formally known as REGN-COV2, creates immunity to COVID-19, the illness caused by the CCP (Chinese Communist Party) virus.
